膳食糖摄入与健康:伞状综述
该伞状综述纳入73项荟萃分析、83项健康结局,评估膳食糖摄入与健康结局的证据质量与偏倚。中等质量证据提示最高 versus 最低糖摄入与体重增加(含糖饮料)和异位脂肪堆积(添加糖)相关;低质量证据提示含糖饮料摄入与痛风、冠心病、全因死亡风险升高相关。作者建议将游离糖或添加糖降至25 g/天以下、含糖饮料限制在每周少于1份。
要点
- 最高 versus 最低膳食糖摄入与体重增加(含糖饮料)和异位脂肪堆积(添加糖)相关,证据质量中等(class IV)。
- 每增加250 mL/天含糖饮料摄入与冠心病风险升高17%(class II)、全因死亡风险升高4%(class III)相关。
- 每增加25 g/天果糖摄入与胰腺癌风险升高22%相关(class III)。
核心结论
- 高膳食糖摄入对健康总体弊大于利,其中心脏代谢疾病方面尤为突出。
- 作者建议将游离糖或添加糖摄入降至25 g/天以下(约6茶匙/天),并将含糖饮料限制在每周少于1份(约200-355 mL/周),以减少糖对健康的不良影响。
研究设计与样本
- 伞状综述,检索PubMed、Embase、Web of Science、Cochrane系统综述数据库并手工检索参考文献列表。
- 纳入评估膳食糖摄入对人类任何健康结局影响的随机对照试验、队列研究、病例对照研究或横断面研究的系统综述与荟萃分析。
- 共纳入73项荟萃分析、83项健康结局,来自8601篇去重文章,其中观察性研究荟萃分析含74项独特结局、随机对照试验荟萃分析含9项独特结局。
主要发现
- 检出膳食糖摄入与18项内分泌/代谢结局、10项心血管结局、7项癌症结局及10项其他结局(神经精神、口腔、肝脏、骨、过敏)之间存在显著有害关联。
- 中等质量证据提示最高 versus 最低膳食糖摄入与体重增加(含糖饮料,class IV证据)和异位脂肪堆积(添加糖,class IV证据)相关。
- 低质量证据提示每周每增加1份含糖饮料摄入与痛风风险升高4%相关(class III证据)。
- 低质量证据提示每增加250 mL/天含糖饮料摄入分别与冠心病风险升高17%(class II证据)和全因死亡风险升高4%(class III证据)相关。
- 低质量证据提示每增加25 g/天果糖摄入与胰腺癌风险升高22%相关(class III证据)。
临床怎么用
- 作者建议将游离糖或添加糖摄入降至25 g/天以下(约6茶匙/天)。
- 作者建议将含糖饮料摄入限制在每周少于1份(约200-355 mL/周)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the quality of evidence, potential biases, and validity of all available studies on dietary sugar consumption and health outcomes. DESIGN: Umbrella review of existing meta-analyses. DATA SOURCES: PubMed, Embase, Web of Science, Cochrane Database of Systematic Reviews, and hand searching of reference lists. INCLUSION CRITERIA: Systematic reviews and meta-analyses of randomised controlled trials, cohort studies, case-control studies, or cross sectional studies that evaluated the effect of dietary sugar consumption on any health outcomes in humans free from acute or chronic diseases. RESULTS: The search identified 73 meta-analyses and 83 health outcomes from 8601 unique articles, including 74 unique outcomes in meta-analyses of observational studies and nine unique outcomes in meta-analyses of randomised controlled trials. Significant harmful associations between dietary sugar consumption and 18 endocrine/metabolic outcomes, 10 cardiovascular outcomes, seven cancer outcomes, and 10 other outcomes (neuropsychiatric, dental, hepatic, osteal, and allergic) were detected. Moderate quality evidence suggested that the highest versus lowest dietary sugar consumption was associated with increased body weight (sugar sweetened beverages) (class IV evidence) and ectopic fatty accumulation (added sugars) (class IV evidence). Low quality evidence indicated that each serving/week increment of sugar sweetened beverage consumption was associated with a 4% higher risk of gout (class III evidence) and each 250 mL/day increment of sugar sweetened beverage consumption was associated with a 17% and 4% higher risk of coronary heart disease (class II evidence) and all cause mortality (class III evidence), respectively. In addition, low quality evidence suggested that every 25 g/day increment of fructose consumption was associated with a 22% higher risk of pancreatic cancer (class III evidence). CONCLUSIONS: High dietary sugar consumption is generally more harmful than beneficial for health, especially in cardiometabolic disease. Reducing the consumption of free sugars or added sugars to below 25 g/day (approximately 6 teaspoons/day) and limiting the consumption of sugar sweetened beverages to less than one serving/week (approximately 200-355 mL/week) are recommended to reduce the adverse effect of sugars on health. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022300982.
引用
- Huang Y, Chen Z, Chen B, et al. Dietary sugar consumption and health: umbrella review. BMJ. 2023. PMID: 37019448. doi:10.1136/bmj-2022-071609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。